Literature DB >> 27861792

Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

M Mosedale1, P B Watkins1.   

Abstract

Drug-induced liver injury (DILI) is a major public health problem. Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US. However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug. Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis. However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI. This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27861792      PMCID: PMC5359062          DOI: 10.1002/cpt.564

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  72 in total

1.  Mitochondrial toxicity assessment in industry--a decade of technology development and insight.

Authors:  Yvonne Will; James Dykens
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-08       Impact factor: 4.481

Review 2.  Genetic basis of drug-induced liver injury: present and future.

Authors:  Thomas J Urban; Ann K Daly; Guruprasad P Aithal
Journal:  Semin Liver Dis       Date:  2014-05-31       Impact factor: 6.115

Review 3.  Bile acids in drug induced liver injury: Key players and surrogate markers.

Authors:  Heiko S Schadt; Armin Wolf; Francois Pognan; Salah-Dine Chibout; Michael Merz; Gerd A Kullak-Ublick
Journal:  Clin Res Hepatol Gastroenterol       Date:  2016-02-10       Impact factor: 2.947

Review 4.  The danger hypothesis applied to idiosyncratic drug reactions.

Authors:  Jinze Li; Jack P Uetrecht
Journal:  Handb Exp Pharmacol       Date:  2010

Review 5.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

Review 6.  Acute liver failure including acetaminophen overdose.

Authors:  Robert J Fontana
Journal:  Med Clin North Am       Date:  2008-07       Impact factor: 5.456

7.  Managing the risk of drug-induced liver injury.

Authors:  P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2013-12       Impact factor: 6.875

8.  Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.

Authors:  Nury M Steuerwald; David M Foureau; H James Norton; Jie Zhou; Judith C Parsons; Naga Chalasani; Robert J Fontana; Paul B Watkins; William M Lee; K Rajender Reddy; Andrew Stolz; Jayant Talwalkar; Timothy Davern; Dhanonjoy Saha; Lauren N Bell; Huiman Barnhart; Jiezhun Gu; Jose Serrano; Herbert L Bonkovsky
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury.

Authors:  Manal M Monshi; Lee Faulkner; Andrew Gibson; Rosalind E Jenkins; John Farrell; Caroline J Earnshaw; Ana Alfirevic; Karin Cederbrant; Ann K Daly; Neil French; Munir Pirmohamed; B Kevin Park; Dean J Naisbitt
Journal:  Hepatology       Date:  2013-02       Impact factor: 17.425

10.  Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors.

Authors:  Jeffrey L Woodhead; William J Brock; Sharin E Roth; Susan E Shoaf; Kim L R Brouwer; Rachel Church; Tom N Grammatopoulos; Linsey Stiles; Scott Q Siler; Brett A Howell; Merrie Mosedale; Paul B Watkins; Lisl K M Shoda
Journal:  Toxicol Sci       Date:  2016-09-21       Impact factor: 4.849

View more
  51 in total

Review 1.  Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy.

Authors:  Shannan R Tujios; William M Lee
Journal:  Liver Int       Date:  2017-09-18       Impact factor: 5.828

Review 2.  Closing the 'phenotype gap' in precision medicine: improving what we measure to understand complex disease mechanisms.

Authors:  Calum A MacRae
Journal:  Mamm Genome       Date:  2019-08-19       Impact factor: 2.957

3.  Novel Mechanisms of Valproate Hepatotoxicity: Impaired Mrp2 Trafficking and Hepatocyte Depolarization.

Authors:  Dong Fu; Panli Cardona; Henry Ho; Paul B Watkins; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2019-07-31       Impact factor: 4.849

Review 4.  Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2019-10-24       Impact factor: 5.810

5.  Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.

Authors:  John F Marcinak; Melvin S Munsaka; Paul B Watkins; Takashi Ohira; Neila Smith
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

6.  Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

Authors:  Dolly A Parasrampuria; Leslie Z Benet; Amarnath Sharma
Journal:  AAPS J       Date:  2018-03-13       Impact factor: 4.009

7.  Generation of multi-cellular human liver organoids from pluripotent stem cells.

Authors:  Wendy L Thompson; Takanori Takebe
Journal:  Methods Cell Biol       Date:  2020-05-22       Impact factor: 1.441

Review 8.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 9.  Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.

Authors:  Mitchell R McGill; Hartmut Jaeschke
Journal:  Expert Rev Mol Diagn       Date:  2018-08-13       Impact factor: 5.225

Review 10.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.